Document is current
Any future updates will be listed below
-
Authors
Figueira-Gonçalves, Juan Marco https://orcid.org/0000-0002-1564-1172
Alcázar-Navarrete, Bernardino https://orcid.org/0000-0003-2356-9366
Casitas-Mateo, Raquel https://orcid.org/0000-0002-1939-1326
González, Jessica https://orcid.org/0000-0002-6847-5315
Gotera-Rivera, Carolina María https://orcid.org/0000-0002-7349-4078
Herrejón-Silvestre, Alberto https://orcid.org/0009-0000-2776-8827
Margallo-Iribarnegaray, Juan https://orcid.org/0000-0001-8805-1600
Martín-Lana, Marta https://orcid.org/0009-0003-1643-5738
Pallarés-Sanmartín, Abel https://orcid.org/0000-0001-9215-7299
Pascual-Guardia, Sergi https://orcid.org/0000-0002-6567-0916
Saura-Vinuesa, Alberto https://orcid.org/0000-0003-2537-3324
Corregidor-García, Carmen https://orcid.org/0009-0009-0260-360X
Fitas, Eunice https://orcid.org/0000-0002-5140-5249
Sánchez-Covisa, Joaquín https://orcid.org/0000-0002-6407-3669
-
Funding
Funding for this research was provided by:
AstraZeneca España
- License Information
-
More Information
Article History
Received: 26 November 2025
Accepted: 5 January 2026
First Online: 19 January 2026
Declarations
:
: Juan Marco Figueira-Gonçalves has received honoraria for speaking engagements and funding for conference attendance from AstraZeneca, Laboratories Esteve, Laboratorios Bial, MundiPharma, Boehringer Ingelheim, Ferrer, Menarini, Rovi, GSK, Chiesi, Novartis, and Gebro Pharma. Bernardino Alcázar-Navarrete declares conflicts of interest for having received consulting fees, research grants, or lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, Grifols, GSK, Laboratorios Bial, Laboratorios Menarini, and Sanofi. Raquel Casitas-Mateo has received honoraria for speaking engagements and funding for conference attendance from AstraZeneca, Laboratorios Bial, Laboratorios Zambón, GSK, Chiesi, Grifols, FAES Farma, and Oximesa. Carolina María Gotera-Rivera declares conflicts of interest for having received consulting fees, research grants, or lectures from AstraZeneca, Chiesi, GSK, and Laboratorios Bial. Alberto Herrejón-Silvestre has received honoraria for speaking engagements and conferences from FAES and Sanofi. Juan Margallo-Iribarnegaray has received honoraria for speaking engagements and funding for conference attendance from AstraZeneca, GSK, Gebro Pharma, and Laboratorios Bial. Marta Martín-Lana has received honoraria for speaking engagements and funding for conference attendance from AstraZeneca, Chiesi, Boehringer Ingelheim, FAES Farma, Laboratorios BIAL, CSL Behring, and Sanofi. Abel Pallarés-Sanmartín has received honoraria for speaking engagements and funding for conference attendance from AstraZeneca, Sanofi, Laboratorios Bial, MundiPharma, Boehringer Ingelheim, Ferrer, GSK, Chiesi, Novartis, and Gebro Pharma. Alberto Suara-Vinuesa has received honoraria for conferences from AstraZeneca, Chiesi, GSK, and Boehringer. Carmen Corregidor-García, Eunice Fitas, and Joaquín Sánchez-Covisa are employees of AstraZeneca. Jessica González and Sergi Pascual-Guardia declare no conflicts of interest.
: The Ethics Committee of Complejo Hospitalario Universitario de Canarias (Santa Cruz de Tenerife) in Spain approved the present study on the 25th of May 2024. This study was performed in accordance with ethical principles that are consistent with the Declaration of Helsinki (1964 and its later amendments), the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and Good Clinical Practice, and the applicable legislation on non-interventional studies and/or observational studies. The Ethics Committee waived the requirement for written informed consent due to the retrospective and non-interventional nature of the study and in accordance with local regulations.
